Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORF-440 in Healthy Participants
NCT06977880Phase 1Completed
- Sponsor
- Morphic Therapeutic
- Start
- Feb 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of LY4292009 (11 arms), sponsored by Morphic Therapeutic. Primary endpoints: Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Event (SAEs), Percentage of Participants with TEAEs and SAEs and 3 more. Started Feb 2025; status: completed.
02
Drugs
LY4292009
Beyond the preview
Go deeper on NCT06977880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06977880.